{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:06:48Z","timestamp":1784642808024,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Xuzhou Municipal Health Commission","award":["Grant No. 2025GG013"],"award-info":[{"award-number":["Grant No. 2025GG013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12026-025-09673-y","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T09:04:16Z","timestamp":1754557456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of belimumab on peripheral blood Breg cells and cytokines in childhood systemic lupus erythematosus"],"prefix":"10.1007","volume":"73","author":[{"given":"Qianqian","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaowen","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"9673_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-021-00985-0","volume":"23","author":"A Charras","year":"2021","unstructured":"Charras A, Smith E, Hedrich C. Systemic lupus erythematosus in children and young people. Curr Rheumatol Rep. 2021;23:1\u201315.","journal-title":"Curr Rheumatol Rep"},{"key":"9673_CR2","doi-asserted-by":"publisher","first-page":"108898","DOI":"10.1016\/j.clim.2021.108898","volume":"234","author":"H Lythgoe","year":"2022","unstructured":"Lythgoe H, McCann L, Hedrich C, Aringer M. Classification of systemic lupus erythematosus in children and adults. Clin Immunol. 2022;234:108898.","journal-title":"Clin Immunol"},{"issue":"2","key":"9673_CR3","first-page":"309","volume":"10","author":"A Mauro","year":"2023","unstructured":"Mauro A, Giani T, Di Mari C, et al. Gastrointestinal involvement in children with systemic lupus erythematosus. Children (Basel). 2023;10(2):309.","journal-title":"Children (Basel)"},{"issue":"5","key":"9673_CR4","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/acr.24827","volume":"74","author":"MO Valenzuela-Almada","year":"2022","unstructured":"Valenzuela-Almada MO, Hocaoglu M, Dabit JY, et al. Epidemiology of childhood-onset systemic lupus erythematosus: a population-based study. Arthritis Care Res. 2022;74(5):728\u201332.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"9673_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard-2022-223035","volume":"82","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82(3):351\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"9673_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","volume":"17","author":"MR Barber","year":"2021","unstructured":"Barber MR, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(9):515\u201332.","journal-title":"Nat Rev Rheumatol"},{"key":"9673_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-021-01040-8","volume":"23","author":"A Di Matteo","year":"2021","unstructured":"Di Matteo A, Smerilli G, Cipolletta E, et al. Imaging of joint and soft tissue involvement in systemic lupus erythematosus. Curr Rheumatol Rep. 2021;23:1\u201312.","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"9673_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41584-021-00739-3","volume":"18","author":"AR Parra S\u00e1nchez","year":"2022","unstructured":"Parra S\u00e1nchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol. 2022;18(3):146\u201357.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"9673_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","volume":"80","author":"A Fanouriakis","year":"2021","unstructured":"Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update \u03bfn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14\u201325.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9673_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s41927-023-00358-3","volume":"7","author":"J Chan","year":"2023","unstructured":"Chan J, Walters GD, Puri P, Jiang SH. Safety and efficacy of biological agents in the treatment of systemic lupus erythematosus (SLE). BMC Rheumatol. 2023;7(1):37.","journal-title":"BMC Rheumatol"},{"issue":"5","key":"9673_CR11","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1177\/09612033241238055","volume":"33","author":"H Oiwa","year":"2024","unstructured":"Oiwa H, Suga T, Hosokawa Y, Araki K. Glucocorticoid-free remission in patients with SLE in the era of biologics: immune complex disease is likely to benefit from current medications. Lupus. 2024;33(5):502\u201310.","journal-title":"Lupus"},{"key":"9673_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103612","author":"M Gatto","year":"2024","unstructured":"Gatto M, Zen M, Cruciani C, Iaccarino L, Doria A. Navigating the landscape of SLE treatment: an expert viewpoint on the rationality and limitations of early biologic intervention. Autoimmun Rev. 2024. https:\/\/doi.org\/10.1016\/j.autrev.2024.103612.","journal-title":"Autoimmun Rev"},{"key":"9673_CR13","doi-asserted-by":"crossref","unstructured":"Wenderfer S, Mason S, Bernal C, da Silva CAA. Lupus nephritis.\u00a0Pediatr Nephrol. 2022:507\u2013539.","DOI":"10.1007\/978-3-030-52719-8_97"},{"key":"9673_CR14","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00431-020-03910-2","volume":"180","author":"P Jongvilaikasem","year":"2021","unstructured":"Jongvilaikasem P, Rianthavorn P. Longitudinal growth patterns and final height in childhood-onset systemic lupus erythematosus. Eur J Pediatr. 2021;180:1431\u201341.","journal-title":"Eur J Pediatr"},{"key":"9673_CR15","doi-asserted-by":"crossref","unstructured":"Yao T-C, Chang S-M, Wu C-S, et al. Association between antenatal corticosteroids and risk of serious infection in children: nationwide cohort study. bmj. 2023;382","DOI":"10.1136\/bmj-2023-075835"},{"issue":"5","key":"9673_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1530\/EJE-21-1085","volume":"186","author":"U Neumann","year":"2022","unstructured":"Neumann U, Van Der Linde A, Krone RE, et al. Treatment of congenital adrenal hyperplasia in children aged 0\u20133 years: a retrospective multicenter analysis of salt supplementation, glucocorticoid and mineralocorticoid medication, growth and blood pressure. Eur J Endocrinol. 2022;186(5):587\u201396.","journal-title":"Eur J Endocrinol"},{"issue":"0102","key":"9673_CR17","doi-asserted-by":"publisher","first-page":"w30088","DOI":"10.4414\/SMW.2022.w30088","volume":"152","author":"S Noetzlin","year":"2022","unstructured":"Noetzlin S, Breville G, Seebach JD, Gastaldi G. Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach. Swiss Med Wkly. 2022;152(0102):w30088\u2013w30088.","journal-title":"Swiss Med Wkly"},{"issue":"4","key":"9673_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40272-021-00457-z","volume":"23","author":"VC Trindade","year":"2021","unstructured":"Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An update on the management of childhood-onset systemic lupus erythematosus. Pediatr Drugs. 2021;23(4):331\u201347.","journal-title":"Pediatr Drugs"},{"issue":"2","key":"9673_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000817","volume":"10","author":"HI Brunner","year":"2023","unstructured":"Brunner HI, Vadhariya A, Dickson C, et al. Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA. Lupus Sci Med. 2023;10(2): e000817.","journal-title":"Lupus Sci Med"},{"key":"9673_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpb.2024.111068","volume":"277","author":"W El-Houseiny","year":"2025","unstructured":"El-Houseiny W, Basher AW, Mahmoud YK, et al. Mitigation of sodium fluoride-induced growth inhibition, immunosuppression, hepatorenal damage, and dysregulation of oxidative stress, apoptosis, and inflammation-related genes by dietary artichoke (Cynara scolymus) leaf extract in Oreochromis niloticus. Comp Biochem Physiol B: Biochem Mol Biol. 2025;277: 111068.","journal-title":"Comp Biochem Physiol B: Biochem Mol Biol"},{"issue":"5","key":"9673_CR21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/14712598.2021.1895744","volume":"21","author":"R Depascale","year":"2021","unstructured":"Depascale R, Gatto M, Zen M, et al. Belimumab: a step forward in the treatment of systemic lupus erythematosus. Expert Opin Biol Ther. 2021;21(5):563\u201373.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"9673_CR22","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.clinthera.2012.02.028","volume":"34","author":"EG Boyce","year":"2012","unstructured":"Boyce EG, Fusco BE. Belimumab: review of use in systemic lupus erythematosus. Clin Ther. 2012;34(5):1006\u201322.","journal-title":"Clin Ther"},{"key":"9673_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","volume":"78","author":"HA Blair","year":"2018","unstructured":"Blair HA, Duggan ST. Belimumab: a review in systemic lupus erythematosus. Drugs. 2018;78:355\u201366.","journal-title":"Drugs"},{"issue":"2","key":"9673_CR24","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S2665-9913(20)30355-6","volume":"3","author":"SZ Sheikh","year":"2021","unstructured":"Sheikh SZ, Scheinberg MA, Wei JC-C, et al. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. Lancet Rheumatol. 2021;3(2):e122\u201330.","journal-title":"Lancet Rheumatol"},{"key":"9673_CR25","doi-asserted-by":"crossref","unstructured":"Hetta HF, Mwafey IM, Batiha GE-S, et al. Cd19+ cd24hi cd38hi regulatory b cells and memory b cells in periodontitis: association with pro-inflammatory and anti-inflammatory cytokines. Vaccines. 2020;8(2):340.","DOI":"10.3390\/vaccines8020340"},{"issue":"29","key":"9673_CR26","doi-asserted-by":"publisher","first-page":"7075","DOI":"10.12998\/wjcc.v11.i29.7075","volume":"11","author":"H Wu","year":"2023","unstructured":"Wu H, Sun H-C, Ouyang G-F. Effect of T-regulatory cells and interleukin-35, interleukin-10, and transforming growth factor-beta on diffuse large B-cell lymphoma. World J Clin Cases. 2023;11(29):7075.","journal-title":"World J Clin Cases"},{"issue":"9","key":"9673_CR27","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1111\/all.14763","volume":"76","author":"K Jansen","year":"2021","unstructured":"Jansen K, Cevhertas L, Ma S, Satitsuksanoa P, Akdis M, van de Veen W. Regulatory b cells, a to z. Allergy. 2021;76(9):2699\u2013715.","journal-title":"Allergy"},{"key":"9673_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108692","volume":"173","author":"G Mendez-Frausto","year":"2021","unstructured":"Mendez-Frausto G, Romero-Aguilera G, Sanchez-Gutierrez R, et al. B regulatory cells associated with changes in biochemical and inflammatory parameters in normal-glycemic individuals, pre-diabetes and T2DM patients. Diabetes Res Clin Pract. 2021;173: 108692.","journal-title":"Diabetes Res Clin Pract"},{"key":"9673_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.980079","volume":"13","author":"KA Kirou","year":"2022","unstructured":"Kirou KA, DallEra M, Aranow C, Anders H-J. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol. 2022;13: 980079.","journal-title":"Front Immunol"},{"issue":"4","key":"9673_CR30","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40744-022-00454-9","volume":"9","author":"SP Huang","year":"2022","unstructured":"Huang SP, Snedecor SJ, Nanji S, Lloyd E, Bell CF. Real-world effectiveness of belimumab in systemic lupus erythematosus: a systematic literature review. Rheumatology and Therapy. 2022;9(4):975\u201391.","journal-title":"Rheumatology and Therapy"},{"issue":"9","key":"9673_CR31","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s40273-022-01166-2","volume":"40","author":"T Otten","year":"2022","unstructured":"Otten T, Riemsma R, Wijnen B, et al. Belimumab for treating active autoantibody-positive systemic lupus erythematosus: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2022;40(9):851\u201361.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"9673_CR32","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","volume":"79","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Abud-Mendoza C, Viola DO, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340\u20138.","journal-title":"Ann Rheum Dis"},{"key":"9673_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12887-021-02659-3","volume":"21","author":"W Quan","year":"2021","unstructured":"Quan W, An J, Li G, et al. Th cytokine profile in childhood-onset systemic lupus erythematosus. BMC Pediatr. 2021;21:1\u201310.","journal-title":"BMC Pediatr"},{"key":"9673_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2023.117609","volume":"551","author":"Z Ye","year":"2023","unstructured":"Ye Z, Zhang T, Xu M, Xu J. Association of soluble ST2 with disease activity in pediatric systemic lupus erythematosus. Clin Chim Acta. 2023;551: 117609.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"9673_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1165","volume":"12","author":"QY Su","year":"2024","unstructured":"Su QY, Luo J, Wang XM, Di JK, Cao YX, Zhang SX. Efficacy, safety and the lymphocyte subsets changes of low-dose IL-2 in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Immunity Inflamm Dis. 2024;12(1): e1165.","journal-title":"Immunity Inflamm Dis"},{"issue":"3","key":"9673_CR36","first-page":"283","volume":"16","author":"Y Park","year":"1998","unstructured":"Park Y, Lee S, Kim D, Lee J, Lee C, Song C. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 1998;16(3):283\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"9673_CR37","doi-asserted-by":"publisher","first-page":"34604","DOI":"10.1038\/srep34604","volume":"6","author":"J Godsell","year":"2016","unstructured":"Godsell J, Rudloff I, Kandane-Rathnayake R, et al. Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. Sci Rep. 2016;6(1):34604.","journal-title":"Sci Rep"},{"issue":"1","key":"9673_CR38","doi-asserted-by":"publisher","first-page":"24820","DOI":"10.1038\/s41598-024-76375-0","volume":"14","author":"N Leerach","year":"2024","unstructured":"Leerach N, Ngaosuwan K, Mahikul W. Regional variations in serum IL-35 levels and association with systemic lupus erythematosus: a systematic review and meta-analysis. Sci Rep. 2024;14(1):24820.","journal-title":"Sci Rep"},{"issue":"1","key":"9673_CR39","doi-asserted-by":"publisher","first-page":"13210","DOI":"10.1038\/s41598-019-49748-z","volume":"9","author":"Z Ye","year":"2019","unstructured":"Ye Z, Jiang Y, Sun D, Zhong W, Zhao L, Jiang Z. The plasma interleukin (IL)-35 level and frequency of circulating IL-35+ regulatory B cells are decreased in a cohort of Chinese patients with new-onset systemic lupus erythematosus. Sci Rep. 2019;9(1):13210.","journal-title":"Sci Rep"},{"key":"9673_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00002","volume":"3","author":"JL Karnell","year":"2012","unstructured":"Karnell JL, Ettinger R. The interplay of IL-21 and BAFF in the formation and maintenance of human B cell memory. Front Immunol. 2012;3: 2.","journal-title":"Front Immunol"},{"issue":"2","key":"9673_CR41","first-page":"172","volume":"31","author":"M Nakou","year":"2013","unstructured":"Nakou M, Papadimitraki ED, Fanouriakis A, et al. Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to the generation of plasma B cells. Clin Exp Rheumatol. 2013;31(2):172\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"1_Supplement","key":"9673_CR42","doi-asserted-by":"publisher","first-page":"99.36","DOI":"10.4049\/jimmunol.182.Supp.99.36","volume":"182","author":"V Nguyen","year":"2009","unstructured":"Nguyen V, Siaton B, Rus V. IL-21 is increased in CD4+ T cells and serum from patients with systemic lupus erythematosus (99.36). J Immunol. 2009;182(1_Supplement):99.36-99.36.","journal-title":"J Immunol"},{"issue":"1","key":"9673_CR43","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/ajt.15546","volume":"20","author":"K Mohib","year":"2020","unstructured":"Mohib K, Cherukuri A, Zhou Y, Ding Q, Watkins SC, Rothstein DM. Antigen-dependent interactions between regulatory B cells and T cells at the T: B border inhibit subsequent T cell interactions with DCs. Am J Transplant. 2020;20(1):52\u201363.","journal-title":"Am J Transplant"},{"key":"9673_CR44","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.3389\/fimmu.2018.01636","volume":"9","author":"M Tarique","year":"2018","unstructured":"Tarique M, Naz H, Kurra SV, et al. Interleukin-10 producing regulatory B cells transformed CD4+ CD25\u2212 into Tregs and enhanced regulatory T cells function in human leprosy. Front Immunol. 2018;9:1636.","journal-title":"Front Immunol"},{"issue":"1","key":"9673_CR45","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41467-024-45056-x","volume":"15","author":"PJ Eggenhuizen","year":"2024","unstructured":"Eggenhuizen PJ, Cheong RM, Lo C, et al. Smith-specific regulatory T cells halt the progression of lupus nephritis. Nat Commun. 2024;15(1):899.","journal-title":"Nat Commun"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-025-09673-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-025-09673-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-025-09673-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:02:27Z","timestamp":1770192147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-025-09673-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9673"],"URL":"https:\/\/doi.org\/10.1007\/s12026-025-09673-y","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional ethics committee approved the study. After fully explaining the study\u2019s purpose, informed consent was obtained from all participants and their legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}